Prospective, Multicenter, Open-Label, Single Arm, Phase 2 Study to Evaluate the Safety and Efficacy of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity in Subjects with Relapsed or Refractory Diffuse Large B-

Administered By

Awarded By

Contributors

Start/End

  • October 17, 2019 - March 16, 2021